🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. FT516

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  2. FT538

    Zafatek

    Solid Tumor, Adult

    phase 1 small molecule terminated

    1 trial

  3. FT825

    Zafatek

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  4. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  5. First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer

    OnKure Therapeutics

    Advanced Solid Tumors, Advanced Breast Cancer

    phase 1 other active

    1 trial

  6. First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  7. First-in-Human trial of DS9051b in participants with advanced solid tumors

    Daiichi Sankyo

    Advanced or Metastatic Adrenocortical Carcinoma (ACC), Metastatic Castration-resistant Prostate Cancer (CRPC)

    phase 1 other active

    1 trial

  8. First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  9. First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterations in MET

    Turn Therapeutics

    Phase 1: Advanced solid tumors harboring genetic alterations in MET

    phase 1 other active

    1 trial

  10. First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  11. GEN1042

    Genmab A/S

    Malignant Solid Tumor

    phase 1 mab active

    1 trial

  12. GK01 Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  13. GLPG0187

    Lakefront Biotherapeutics NV

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  14. GLPG0555 solid dispersion

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  15. GMX1777

    Teva Pharma GmbH

    Solid Tumors and Lymphomas

    phase 1 small molecule terminated

    1 trial

  16. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  17. HBT-708

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  18. HEC68498

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. HPV-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 1 mab active

    1 trial

  20. HRS-2329 Tablet

    Jian Li

    Advanced Solid Tumors Harboring RAS Mutations or Amplifications

    phase 1 small molecule active

    1 trial

  21. HS-IT101 Injection

    Qingdao University

    Solid Tumor

    phase 1 small molecule active

    1 trial

  22. HW071021 Tablets

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  23. HW071021 Tablets

    Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  24. HWS116 Injection

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources